Comparative Pharmacology
Head-to-head clinical analysis: PLEGISOL IN PLASTIC CONTAINER versus PORTALAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLEGISOL IN PLASTIC CONTAINER versus PORTALAC.
PLEGISOL IN PLASTIC CONTAINER vs PORTALAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PLEGISOL is an extracellular-type crystalloid cardioplegic solution used for myocardial protection during cardiac surgery. Its mechanism involves inducing rapid cardiac arrest by high potassium concentration (depolarizing arrest), reducing myocardial oxygen demand, and providing buffering capacity via tromethamine to maintain pH. The solution also contains magnesium to stabilize membranes and mannitol as an osmotic agent to reduce edema.
Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to short-chain fatty acids (e.g., acetic, lactic, and formic acid), resulting in acidification of colonic contents and an increase in osmotic pressure, which stimulates bowel evacuation. In hepatic encephalopathy, acidification reduces blood ammonia levels by converting NH3 to NH4+ in the colon, inhibiting ammonia absorption.
Administered as an intraperitoneal infusion for organ preservation. Typical adult dose: 2.5-3.0 liters for kidney, 2.5-3.0 liters for liver, 3.0-4.0 liters for pancreas, single dose prior to procurement.
Initial: 15-30 mL (10-20 g lactulose) orally, 2-3 times daily; titrate to 2-3 soft stools daily. For acute hepatic encephalopathy: 30-45 mL (20-30 g) orally every hour until evacuation, then 3-4 times daily.
None Documented
None Documented
Not applicable; Plegisol is not a systemically active drug. Its cardioplegic effect is immediate upon perfusion into coronary arteries and dissipates upon reperfusion. The solution's components have endogenous half-lives (e.g., potassium: 1-1.5 h in plasma), but this is not clinically relevant for the product.
1.7-2.0 hours (terminal); clinical context: short t1/2 allows rapid dose adjustment in hepatic encephalopathy.
Plegisol is an extracellular cardioplegic solution; its components (electrolytes and calcium) are not metabolized. Elimination of infused volume occurs primarily via renal excretion (approx. 95%) as unchanged water and electrolytes; minor biliary/fecal elimination (<5%) accounts for negligible electrolyte loss.
Renal: ~40% as unchanged drug; fecal: ~60% as metabolites (biliary excretion of conjugates and lactulose).
Category C
Category C
Osmotic Laxative
Osmotic Laxative